Clinical Immunology and Immunopathology
Characterization of C1q-binding IgG complexes in systemic lupus erythematosus☆
References (39)
- et al.
Advan. Protein Chem.
(1979) - et al.
Amer. J. Med.
(1980) - et al.
Lancet
(1977) - et al.
J. Clin. Invest.
(1980) - et al.
J. Immunol. Methods
(1979) - et al.
Arch. Biochem. Biophys.
(1971) - et al.
J. Biol. Chem.
(1973) - et al.
Clin. Immunol. Immunopathol.
(1981) - et al.
J. Immunol. Methods
(1976) - et al.
J. Exp. Med.
(1971)
Amer. J. Pathol.
J. Clin. Invest.
Nature (London)
Biochem. J.
J. Exp. Med.
J. Immunol.
Clin. Exp. Immunol.
J. Immunol.
Bull. Rheum. Dis.
Cited by (90)
C1q, antibodies and anti-C1q autoantibodies
2015, Molecular ImmunologyCitation Excerpt :By using high-salt buffers it was possible to discriminate between IC binding and binding of these monomeric anti-C1q autoantibodies (Kohro-Kawata et al., 2002). These anti-C1q autoantibodies target only ligand bound, solid-phase, C1q and not fluid-phase C1q (Agnello et al., 1971; Uwatoko et al., 1984) (Fig. 2). The team of Prof. Daha played an important role in highlighting the importance of anti-C1q in routine clinical diagnostics (Coremans et al., 1992; Siegert et al., 1992; Trouw et al., 2004a).
Autoantibodies to C1q
2014, Autoantibodies, Third EditionAnti-C1q antibodies as markers of renal compromise in patients with systemic lupus erythematosus
2013, Revista Colombiana de ReumatologiaAutoantibodies to C1q
2013, Autoantibodies: Third EditionAnti-C1q antibodies and systemic lupus erythematosus in the Tunisian population
2013, Pathologie BiologieCitation Excerpt :However, soluble antigens such as complement components are also targeted [2]. The classical pathway of complement is activated by the binding of C1q to complexed immunoglobulins or C-reactive protein and it was demonstrated that antibodies against C1q are present during SLE [3,4]. The presence of anti-C1q antibodies is correlated with reduced C1q levels and associated with more severe illness and nephritis in patients with SLE [5,6].
- ☆
Supported in part by a grant for Autoimmune Diseases from the Ministry of Health and Welfare, Japan.